Amanta Healthcare Ltd
We are a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal ("ABFS") and Injection Strech Blow Moulding ("ISBM") technology. We manufacture large volume parenterals ("LVPs") and small volume parenterals ("SVPs") in six therapeutic segments. In addition to that, we also manufacturer medical devices. We manufacture fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in medical device segment. We offer wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume ranging from 2ml to 1000 ml. Our formulation and development operations help us to develop new formulation as well as modify improve the formulation for our own brand as well as our customers for product partnering business. We have a dedicated Formulation and Development ("F&D") and quality control laboratory located at our manufacturing facility in Hariyala, District Kheda, Gujarat, India. We have four LVPs manufacturing lines, which include two lines of conventional single port containers with ABFS technology and two lines for SteriPort products with ISBM technology. Similarly, we have three operational SVPs manufacturing lines, which includes two ABFS lines and one conventional three-piece container filling lines. Our manufacturing facility has good manufacturing practices ("GMP") certifications from the Food & Drugs Control Administration, Gujarat, in conformity with the format recommended by the World Health Organization (the "WHO"), the GMP for formulations from Cambodia, Sudan, Philippines, Zimbabwe. We also have certificate from DNV for exports of medical device products. Our cGMP capabilities allow us to offer our customers various products of sterile liquid form in product categories of quinolones, anti-biotics, anti-fungal, diuretic, anti-anaerobic, Ophthalmic, Respiratory etc.
Timeline
Subscription
Reports
Offer Details
Terms
Application Sizes
Managers & Registrar
Ownership & Proceeds
Shareholding
Objects of the Issue
- Funding capital exp requirements for civil construction work and towards purchase of equipment plant and machinery for setting up new mfg line of SteriPort
- Funding capital exp requirements towards purchase of equipment plant and machinery for setting up new line for SVP at
- General corporate purposes
Financials
Profit & Loss
| Financial Year | FY23 | FY24 | FY25 | FY26 | Latest |
|---|---|---|---|---|---|
| RevenueCr | 259 | 280 | 275 | 288 | 291 |
| Operating ProfitCr | 53 | 57 | 60 | 60 | 60 |
| OPM% | 20.4 | 20.5 | 21.7 | 20.8 | 20.4 |
| PBTCr | 3 | 5 | 15 | 21 | 21 |
| PATCr | -2 | 4 | 11 | 15 | 15 |
| EPS | -1 | 1 | 4 | 4 | 4 |
Balance Sheet
| Financial Year | FY23 | FY24 | FY25 | FY26 | Latest |
|---|---|---|---|---|---|
| Equity CapitalCr | 27 | 27 | 29 | 39 | - |
| ReservesCr | 36 | 39 | 68 | 181 | - |
| BorrowingsCr | 216 | 211 | 204 | 244 | - |
| Fixed AssetsCr | - | - | 217 | 207 | - |
| Total AssetsCr | 374 | 352 | 382 | 558 | - |
Cash Flow
| Financial Year | FY23 | FY24 | FY25 | FY26 | Latest |
|---|---|---|---|---|---|
| Operating Cash FlowCr | 43 | 58 | 47 | 48 | - |
| Investing Cash FlowCr | -7 | -10 | -24 | -94 | - |
| Financing Cash FlowCr | -42 | -46 | -23 | 126 | - |
| Net Cash FlowCr | -6 | 1 | -1 | 81 | - |
Strengths & Risks
- Well established manufacturer of pharmaceutical formulations with diverse product portfolio and diverse market.
- Large manufacturing capabilities.
- Wide Domestic and International Marketing Network.
- Experienced management team supported by large, diverse and skilled work force.
- Expansion of our manufacturing capacities.
- National Sales business.
- Expand National Sales Network.
- Expand the wallet share of existing customers and develop new customers.
- Our Company's entire manufacturing facility is located at a single location, and all of the Company's manufactured products are produced from such facility in village Hariyala, district Kheda, Gujarat. Any delay in production at, or shutdown of, our manufacturing facility due to various factors such as shortage of electrical power or water resources, political instability, industrial accidents or machinery breakdowns, severe weather conditions, natural disasters, and outbreak of infectious diseases may in turn adversely affect our business, financial condition and results of operations.
- Any manufacturing or quality control concerns or our inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by our clients and distributors, which could have an adverse effect on our business, results of operations, financial condition and cash flows.
- Our Company is involved in a certain material litigation and an adverse outcome in this proceeding may adversely affect our business, financial condition and growth strategy.
- We may not be able to improve our profit margins and profits in the future.
- Our Company had issued Equity Shares to more than 49 investors in the past and as a matter of abundant caution for better corporate governance, our Company has given an exit offer to the eligible shareholders.
- Finance cost of the Company has been very high and finance cost of the company for the Fiscal 2025, Fiscal 2024, and Fiscal 2023 constituted 45.78%, 57.25% and 62.64% of the Restated Earnings before interest, tax, depreciation and amortization (EBITDA). If company is unable to control the finance cost in future, it may adversely affect business, results of operations, financial condition and cash flows.